Search results

Technologies 3

• DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
  Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens.
• Biomaterial Scaffolds for T Cell Expansion
  Immunotherapy, or tweaking the body’s own immune system to treat disease, is attracting significant attention in the medical field for its potential to offer long-lasting cures with fewer side effects than chemotherapy or other drugs. One type of immunotherapy involves isolating T cells (a type of white blood cell) from a patient’s body, sometimes modifying...
• NanoRx: Mechanically-Activated Drug Targeting
  The Wyss team has developed a novel drug targeting nanotechnology that is activated locally by mechanical forces, either endogenous high shear stresses in blood created by vascular occlusion or mechanical energy applied locally using low-energy ultrasound radiation. Today, vascular blockage is the leading cause of death and disability in United States and Europe. Current therapies...

News 8

View all

• Research Spotlights
  
  DNA nanostructures suit up for future missions
  February 21, 2020
• Press Release
  
  A golden ticket to faster muscle recovery
  October 1, 2018
• Press Release
  
  Single-stranded DNA and RNA origami go live
  December 14, 2017

Multimedia 2

• 

  Video/Animation
  NanoRx: Clot-Busting Nanotherapeutic
  In this animation, learn how the Wyss Institute clot-busting nanotherapeutic is activated by fluid high shear force – which occurs where blood flows through vessels narrowed by obstruction – to specifically target clots and dissolve them away. By pairing this drug with an intra-arterial device that restores blood flow to complete obstructions, the drug-device combination...

• 

  Video/Animation
  Clot-busting nanotherapeutic
  Wyss Core Faculty member Donald E. Ingber describes the clot-busting nanotherapeutic. Credit: Wyss Institute at Harvard University